Edition:
United States

Obalon Therapeutics Inc (OBLN.OQ)

OBLN.OQ on NASDAQ Stock Exchange Global Market

7.68USD
3:59pm EST
Change (% chg)

$0.18 (+2.40%)
Prev Close
$7.50
Open
$7.52
Day's High
$7.79
Day's Low
$7.28
Volume
4,837
Avg. Vol
9,237
52-wk High
$13.18
52-wk Low
$7.14

Latest Key Developments (Source: Significant Developments)

Obalon Therapeutics Q3 loss per share $0.55
Friday, 3 Nov 2017 07:29am EDT 

Nov 3 (Reuters) - Obalon Therapeutics Inc :Obalon announces third quarter 2017 financial results.Q3 revenue $2.8 million versus I/B/E/S view $2.9 million.Q3 loss per share $0.55.Q3 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.  Full Article

Obalon Therapeutics & Sono Bello announce agreement to offer novel weight loss treatment
Thursday, 2 Nov 2017 04:06pm EDT 

Nov 2 (Reuters) - Obalon Therapeutics Inc :Obalon Therapeutics Inc and Sono Bello announce agreement to offer novel weight loss treatment in Sono Bello centers.Obalon Therapeutics Inc - ‍co, Sono Bello announced that they had reached an agreement to begin offering Obalon balloon system​.Obalon Therapeutics Inc - ‍Obalon balloon system will be exclusive non-invasive weight loss technology offered in Sono Bello centers​.  Full Article

Obalon Therapeutics files for mixed shelf of up to $100 mln
Wednesday, 1 Nov 2017 07:39pm EDT 

Nov 1 (Reuters) - Obalon Therapeutics Inc ::Files for mixed shelf of up to $100 million - SEC filing‍​.Says in addition, selling stockholder may offer and sell up to 150,000 shares of co's common stock.  Full Article

Obalon Q2 loss per share $0.46
Wednesday, 2 Aug 2017 07:59am EDT 

Aug 2 (Reuters) - Obalon Therapeutics Inc :Obalon announces second quarter 2017 financial results.Q2 revenue $2.0 million versus i/b/e/s view $1.7 million.Q2 loss per share $0.46.Q2 earnings per share view $-0.44 -- Thomson Reuters I/B/E/S.Obalon therapeutics inc - ‍at june 30, 2017, cash, cash equivalents and short-term investments were $60.7 million and long-term debt was $10.0 million.​.  Full Article

Obalon receives regulatory approvals to commercialize in select Middle East markets
Thursday, 11 May 2017 08:02am EDT 

May 11 (Reuters) - Obalon Therapeutics Inc :Obalon receives regulatory approvals to commercialize in select middle east markets.Obalon therapeutics inc - intends to fulfill an initial order to its middle east distributor, bader sultan, during q2 of 2017.  Full Article

Obalon Q1 loss per share $0.47
Wednesday, 10 May 2017 08:01am EDT 

May 10 (Reuters) - Obalon Therapeutics Inc :Obalon announces first quarter 2017 financial results.Q1 revenue $1.5 million versus i/b/e/s view $1.3 million.Q1 loss per share $0.47.Q1 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

Obalon Therapeutics Q4 loss per share $0.51
Thursday, 23 Feb 2017 07:45am EST 

Obalon Therapeutics Inc : Obalon Therapeutics Inc announces fourth quarter and full year 2016 financial results . Q4 loss per share $0.51 . Q4 revenue $800,000 versus I/B/E/S view $697,000 .Q4 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.  Full Article

Obalon Therapeutics says announced pricing of IPO of 5 mln shares at $15/shr
Wednesday, 5 Oct 2016 08:29pm EDT 

Obalon Therapeutics Inc : Obalon therapeutics announces pricing of initial public offering .Says announced pricing of its ipo of 5 million shares of its common stock at a price to public of $15.00 per share.  Full Article

Obalon Therapeutics says announced pricing of IPO of 5 mln shares at $15/shr
Wednesday, 5 Oct 2016 07:46pm EDT 

Obalon Therapeutics Inc : Obalon therapeutics announces pricing of initial public offering .Says announced pricing of its ipo of 5 million shares of its common stock at a price to public of $15.00 per share.  Full Article

BRIEF-Obalon Therapeutics Q3 loss per share $0.55

* Q3 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: